Kymera Therapeutics, Inc. (KYMR)
Stock Price:
$29.22 USD
-1.42 (-4.63%)
Updated Sep 21, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.30B |
| Revenue (ttm) |
9.50M |
| Net Income (ttm) |
-47.85M |
| Shares Out |
44.44M |
| EPS (ttm) |
-1.15 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 21, 2020 |
| Last Price |
$29.22 |
| Previous Close |
$30.64 |
| Change ($) |
-1.42 |
| Change (%) |
-4.63% |
| Day's Open |
30.16 |
| Day's Range |
28.61 - 31.14 |
| Day's Volume |
255,602 |
| 52-Week Range |
25.43 - 37.75 |
More Stats
| Market Cap |
1.30B |
| Enterprise Value |
1.16B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.44M |
| Float |
22.92M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.15 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
196,509 |
| Short Ratio |
0.21 |
| Short % of Float |
0.60% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
136.71 |
| PB Ratio |
12.42 |
| Revenue |
9.50M |
| Operating Income |
n/a |
| Net Income |
-47.85M |
| Free Cash Flow |
n/a |
| Net Cash |
136.86M |
| Net Cash / Share |
3.08 |
| Gross Margin |
-360.29% |
| Operating Margin |
n/a |
| Profit Margin |
-503.78% |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$34.67*
(18.65% upside)
Low
27.0
Current: $29.22
High
42.0
Target: 34.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 2.93 | - |
| Gross Profit | 2.93 | - |
| Operating Income | -42.21 | -21.45 |
| Net Income | -41.25 | -21.47 |
| Shares Outstanding | 2.71 | 1.88 |
| Earnings Per Share | -15.23 | -11.45 |
| Operating Cash Flow | 17.91 | -17.86 |
| Capital Expenditures | -0.53 | -1.36 |
| Free Cash Flow | 17.37 | -19.22 |
| Cash & Equivalents | 91.96 | 41.26 |
| Total Debt | 21.19 | 0.70 |
| Net Cash / Debt | 70.76 | 40.57 |
| Assets | 117 | 44.23 |
| Liabilities | 82.03 | 5.24 |
| Book Value | -74.41 | -34.44 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kymera Therapeutics, Inc. |
| Country |
United States |
| Employees |
55 |
| CEO |
Nello Mainolfi |
Stock Information
| Ticker Symbol |
KYMR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KYMR |
| IPO Date |
August 21, 2020 |
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.